READER QUESTIONS / ANSWERED
The questions the headline leaves out
Definitions, evidence boundaries, and the difference between a body-composition result and a functional result.
What is tesamorelin?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It stimulates the pituitary gland to release the body's own growth hormone and increases downstream IGF-1 signaling. Its approved United States use is reducing excess abdominal fat in adults with HIV-associated lipodystrophy [2]. The cited evidence should not be generalized into a broad weight-loss or muscle-enhancement claim. Its regulatory status and its popular reputation are therefore much farther apart than a casual summary may suggest.
What does tesamorelin do in studies?
Human trials in HIV-associated lipodystrophy report reductions in visceral and liver fat, while pooled randomized evidence also reports an increase in lean body mass [1][3][5][6]. Those are body-composition findings. The studies in this corpus do not establish that tesamorelin improves grip, gait, lifting capacity, or other direct measures of muscle function. A scan can describe compartments while leaving the practical meaning of the change unresolved.
How does tesamorelin work?
It activates growth hormone-releasing hormone receptors in the anterior pituitary, increasing pulsatile growth hormone release and downstream IGF-1. Those signals affect fat metabolism, especially visceral adipose tissue. A small mechanistic study documented changes in overnight growth hormone and IGF-1 [4]. Mechanism supports plausibility; it does not prove every claimed outcome. Direct strength testing would still be needed to move from pathway logic to a functional conclusion.
What does the MOTS-c peptide do?
In cell and animal research, MOTS-c acts as a mitochondrial stress signal connected to AMPK, nuclear stress-response genes, CK2, muscle glucose uptake, and atrophy pathways [8][10][12]. Animal studies also report grip, gait, and treadmill outcomes [11]. No human efficacy trial in this corpus shows that administered MOTS-c improves those functions in people. The functional endpoints are unusually direct, but their species makes translation the decisive unresolved issue.
What are the known negative effects of MOTS-c?
The central problem is that controlled human safety evidence is missing. The corpus contains no completed human intervention trial, validated pharmacokinetics, or established adverse-effect frequency. That means claims of safety are premature. Research-chemical quality and anti-doping restrictions add separate concerns. Animal findings cannot supply a safe human-use conclusion. Unknown frequency is not evidence that adverse effects are rare; it is evidence that frequency has not been established.
Does MOTS-c have human evidence?
Yes, but not human efficacy evidence from administering the peptide. A small prospective cohort of chronic hemodialysis patients found that circulating MOTS-c was associated with a composite clinical outcome and modestly improved risk prediction [9]. That is an observational biomarker finding. It cannot show that giving MOTS-c causes benefit, improves strength, or changes weight. Biomarker association and treatment effect are separate claims that require separate study designs.
What is tirzepatide?
Tirzepatide is a synthetic prescription peptide that activates both GIP and GLP-1 receptors [14]. These incretin pathways influence glucose-dependent insulin secretion, glucagon, gastric emptying, appetite, and food intake. Randomized trials support substantial effects on body weight and glycemic control [13][16][17]. Those endpoints define the established evidence; muscle performance remains a different research question.
How does tirzepatide compare with semaglutide?
In a direct randomized trial in adults with obesity without diabetes, tirzepatide produced greater mean weight loss than semaglutide at the study endpoint [13]. That is a comparison of body-weight change under a specific protocol. It does not show that tirzepatide preserves strength better or produces a superior muscle-function outcome.
What is semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist used in prescription products for defined metabolic indications. It affects glucose-dependent insulin secretion, glucagon release, stomach emptying, and appetite. Its evidence includes randomized trials for body weight, cardiovascular events, and kidney outcomes in specific populations [18][19][20]. That breadth should be preserved without pretending every trial addressed body composition or physical function.
What are the main semaglutide safety themes?
A dedicated review describes gastrointestinal effects as the dominant pattern, notes increased biliary disease, and says rare pancreatic and thyroid signals remain unresolved because events are uncommon [21]. Community accounts may describe similar or additional experiences, but those accounts are anecdotal, not clinical evidence and cannot establish cause or frequency.
Is lean mass the same as muscle mass?
No. Lean mass is a broad body-composition category that includes more than skeletal muscle. Even a more muscle-focused scan estimates tissue quantity, not strength, power, endurance, or movement quality. A claim about lean mass should therefore remain a composition claim unless a study also reports direct functional tests.
Can these studies show which compound is best for strength?
No. The studies differ in species, populations, mechanisms, and endpoints. Tesamorelin has human lean-mass data [1]. MOTS-c has direct function tests mainly in mice [11]. Tirzepatide and semaglutide have large human weight and metabolic trials [13][16][18][19][20]. No common head-to-head strength protocol spans all four compounds.